Amneal公布二季度业绩超预期并上调2026年全年指引

–
Q2 2026
Net Revenue of
$796 million
; GAAP Net
Income
of
$58 million
; Diluted
Income
per Share of
$0.18
–
– Adjusted EBITDA of
$206 million
; Adjusted Diluted EPS of
$0.30
–
– Raising
2026
Full Year Guidance –
– Successful Debt Repricing in July Reduces Interest Cost –
BRIDGEWATER, N.J., July 30, 2026 (GLOBE NEWSWIRE) --
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX)
(“Amneal” or the “Company”) today announced its results for the second quarter ended June 30, 2026.
“Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and the contributions from multiple growth drivers. This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year. We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal, further diversifying our portfolio and expanding our long-term growth opportunities. As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal’s outlook and the breadth and durability of the opportunities across our portfolio,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.
Second
Quarter
2026
Results
Net revenue in the second quarter of 2026 was $796 million, an increase of 10% compared to $725 million in the second quarter of 2025. Specialty net revenue increased 17%, driven by key branded products, including CREXONT
®
, BREKIYA
®
autoinjector, and UNITHROID
®
. Affordable Medicines net revenue increased 13%, driven by strong performance of our complex portfolio, including women’s health products, and new product launches. AvKARE net revenue decreased 4% due to a decline in the low margin distribution channel partially offset by growth in the government channel.
Net income attributable to Amneal Pharmaceuticals, Inc. was $58 million in the second quarter of 2026 compared to net income of $22 million in the second quarter of 2025, an increase of 157%, as higher revenue and gross profit, lower interest expense, and a lower tax provision more than offset increased SG&A expense.
Adjusted EBITDA in the second quarter of 2026 was $206 million, an increase of 12% compared to the second quarter of 2025, reflecting higher revenue and gross profit.
Diluted income per share in the second quarter of 2026 was $0.18 compared to diluted income per share of $0.07 for the second quarter of 2025, an increase of 157%, due to the aforementioned factors. Adjusted diluted earnings per share in the second quarter of 2026 was $0.30, an increase of 20% compared to $0.25 for the second quarter of 2025.
The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information.
Debt Repricing Further Reduces Future Interest Cost
In July 2026, the Company launched a repricing of its $2.084B Term Loan B, which will reduce the interest rate by 50 basis points from Secured Overnight Financing Rate (“SOFR”) plus 300 basis points to SOFR plus 250 basis points. The repricing is expected to close as early as August 3, 2026.
The Company also intends to obtain an additional $350 million Term Loan B financing to fund a portion of the purchase price of Kashiv Biosciences, as previously disclosed. Such additional Term Loans are expected to be incurred at the closing of the Kashiv acquisition at the reduced pricing. The repricing transaction is expected to generate about $12 million in annual cash interest savings and contribute towards the Company’s goal to reduce net leverage to below 3.0x by 2028.
Raising
2026
Full Year Guidance
We are raising select full year 2026 guidance metrics.
Updated Guidance
Prior Guidance
Net revenue
$3.10 billion - $3.20 billion
$3.05 billion - $3.15 billion
Adjusted EBITDA
(1)
$750 million - $780 million
$740 million - $770 million
Adjusted diluted EPS
(2)
$0.96 - $1.06
$0.95 - $1.05
Operating cash flow
(3)
$350 million - $400 million
$350 million - $400 million
Operating cash flow, excluding discrete items
(4)
$375 million - $425 million
$375 million - $425 million
Capital expenditures
(5)
~$150 million
~$110 million
(1)
Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.
(2)
Accounts for 35% non-controlling interest in AvKARE. Assumes approximately 340 million weighted-average diluted shares outstanding for the year ending December 31, 2026.
(3)
Represents cash provided by operating activities.
(4)
Excludes discrete items such as opioid settlement costs of approximately $36 million and Kashiv acquisition and integration costs of approximately $30 million.
(5)
Reflects estimated capital expenditures and deposits for future acquisition of property, plant, and equipment.
Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.
Conference Call Information
Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, July 30, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at
https://investors.amneal.com
. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 901153095. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website:
https://help.events.q4inc.com/eahc/international-dial-in-numbers
.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit
amneal.com
and follow us on LinkedIn.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions